Utility of the ACD-GENE-CLI Score in Asian Patients with Critical Limb Ischemia Undergoing Endovascular Interventions
-
- Chang Wei-Ting
- School of Medicine and Doctoral Program of Clinical and Experimental Medicine, College of Medicine and Center of Excellence for Metabolic Associated Fatty Liver Disease, National Sun Yat-sen University Division of Cardiology, Department of Internal Medicine, Chi Mei Medical Center
-
- Huang Po-Sen
- Division of Cardiology, Department of Internal Medicine, Chi Mei Medical Center
-
- Su Li-Wei
- Division of Cardiology, Department of Internal Medicine, Chi Mei Medical Center
-
- Liao Chia-Te
- Division of Cardiology, Department of Internal Medicine, Chi Mei Medical Center School of Medicine, College of Medicine, National Sun Yat-Sen University Studies Coordinating Centre, Research Unit Hypertension and Cardiovascular Epidemiology, KU Leuven Department of Cardiovascular Sciences, University of Leuven
-
- Siong Toh Han
- Department of Intensive Care Medicine, Chi Mei Medical Centre Department of Health and Nutrition, Chia Nan University of Pharmacy and Science
-
- Chen Yi-Chen
- Department of Medical Research, Chi-Mei Medical Center
-
- Ho Chung‑Han
- Department of Medical Research, Chi-Mei Medical Center Department of Information Management, Southern Taiwan University of Science and Technology
-
- Chen Zhih-Cherng
- Division of Cardiology, Department of Internal Medicine, Chi Mei Medical Center School of Medicine, College of Medicine, National Sun Yat-Sen University
-
- Hsu Po-Chao
- Division of Cardiology, Department of Internal Medicine, Kaohsiung Medical University Hospital Department of Internal Medicine, Faculty of Medicine, School of Medicine, Kaohsiung Medical University
-
- Hong Chon-Seng
- Division of Cardiology, Department of Internal Medicine, Chi Mei Medical Center Department of Health and Nutrition, Chia Nan University of Pharmacy and Science
抄録
<p> Aims: Critical limb ischemia (CLI) is an emerging public health threat and lacks a reliable score for predicting the outcomes. The Age, Body Mass Index, Chronic Kidney Disease, Diabetes, and Genotyping (ABCD-GENE) risk score helps identify patients with coronary artery disease who have cytochrome P450 2C19 (CYP2C19) polymorphism-related drug resistance and are at risk for cardiovascular adverse events. However, its application to CLI remains unknown. In this study, we aim to validate a modified ACD-GENE-CLI score to improve the prediction of major adverse limb events (MALEs) in patients with CLI receiving clopidogrel.</p><p>Methods: Patients with CLI receiving clopidogrel post-endovascular intervention were enrolled prospectively in two medical centers. Amputation and revascularization as MALEs were regarded as the outcomes.</p><p>Results: A total of 473 patients were recruited, with a mean follow-up duration of 25 months. Except for obesity, old age, diabetes, chronic kidney disease (CKD), and CYP2C19 polymorphisms were significantly associated with MALEs. Using bootstrap regression analysis, we established a modified risk score (ACD-GENE-CLI) that included old age (≥ 65 years), diabetes, CKD, and CYP2C19 polymorphisms. At a cutoff value of 8, the ACD-GENE-CLI score was superior to the CYP2C19 deficiency only, and the conventional ABCD-GENE score in predicting MALEs (area under the curve: 0.69 vs. 0.59 vs. 0.67, p=0.01). The diagnostic ability of the ACD-GENE-CLI score was consistent in the external validation. Also, Kaplan–Meier curves showed that in CYP2C19 deficiency, the ABCD-GENE and ACD-GENE-CLI scores could all differentiate patients with CLI who are free from MALEs.</p><p>Conclusions: The modified ACD-GENE-CLI score could differentiate patients with CLI receiving clopidogrel who are at risk of MALEs. Further studies are required to generalize the utility of the score.</p>
収録刊行物
-
- Journal of Atherosclerosis and Thrombosis
-
Journal of Atherosclerosis and Thrombosis 31 (5), 572-586, 2024-05-01
一般社団法人 日本動脈硬化学会